Impact of early intrapatient variability of tacrolimus concentrations on the risk of graft-versus-host disease after allogeneic stem cell transplantation using high-dose post-transplant cyclophosphamide

HIGHLIGHTS

• who: Daniel N. Marco and collaborators from the Oncology, Hospital Clu00ednic, IDIBAPS, Barcelona, Spain have published the research work: Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide, in the Journal: Pharmaceuticals 2022, 15, 1529. of /2022/
• what: This study evaluated Tac IPV based on C0 measurements in the early period after alloHSCT in patients receiving PTCy-based GVHD prophylaxis regimens and analyzed the effects of Tac IPC on the incidence of acute GVHD (aGVHD). The present . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.